Results 251 to 260 of about 112,622 (301)

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. [PDF]

NAR Cancer
Illuzzi G, Galbiati A, Staniszewska AD, Hanson R, Michaloglou C, Cooke SL, Uznańska K, Białecka M, Solarczyk K, Dev HS, Massie CE, Albertella MR, Leo E, Forment JV, O'Connor MJ.   +14 more
europepmc   +1 more source

Letter Re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according To BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor. [PDF]

ESMO Open
Önder AH, Çatlı MM.
europepmc   +1 more source

Multimodal data integration with machine learning for predicting PARP inhibitor efficacy and prognosis in ovarian cancer. [PDF]

Front Oncol
Xiong X, Cai L, Yang Z, Cao Z, Wu N, Ni Q.   +5 more
europepmc   +1 more source

PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced. [PDF]

NAR Cancer
Goel K, Venkatappa V, Krieger KL, Chen D, Sreekumar A, Gassman NR.   +5 more
europepmc   +1 more source

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencing

Nesic K, Geissler F, Xu L, Kyran E, Beard S, Vandenberg CJ, Liddell B, Olechnowicz SW, Topp M, McNally O, Ratnayake G, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DD, Pappenfuss T, Zhang F, Dobrovic A, Waddell N, Scott CL, Kondrashova O, Wakefield MJ.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tackling PARP inhibitor resistance

Trends in Cancer, 2021
Homologous recombination-deficient (HRD) tumours, including those harbouring mutations in the BRCA genes, are hypersensitive to treatment with inhibitors of poly(ADP-ribose) polymerase (PARPis). Despite high response rates, most HRD cancers ultimately develop resistance to PARPi treatment through reversion mutations or genetic/epigenetic alterations to
Fugger, Kasper, Hewitt, Graeme, West, Stephen C., Boulton, Simon J.   +3 more
openaire   +3 more sources

PARP Inhibitors

Current Breast Cancer Reports, 2011
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire   +2 more sources

Expanding biomarkers for PARP inhibitors

Nature Cancer, 2022
International audience ; The efficacy of talazoparib and other PARP inhibitors has been primarily reported in germline BRCA mutation carriers. New results establish germline mutations in PALB2, but not in other homologous recombination (HR) genes, as targets for PARP inhibitors in breast cancer, whereas the added predictive value of HR signatures ...
Florence Coussy, Francois-Clement Bidard
openaire   +3 more sources

PARP inhibitor combination therapy

Critical Reviews in Oncology/Hematology, 2016
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality.
Dréan, A, Lord, CJ, Ashworth, A
openaire   +3 more sources

Adverse events of PARP inhibitors

Česká gynekologie, 2021
An evaluation of the safety of poly-ADP-ribose-polymerase inhibitors (PARPi) in ovarian cancer treatment.An analysis of the studies on PARP inhibitors, a summary of the most common and serious adverse events.According to the studies, the most common adverse events of PARPi include hematotoxicity, nausea and vomiting.
Martina, Romanová, Jaroslav, Klát
openaire   +2 more sources